Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer

MeSH terms

• Carcinoma, Non-Small-Cell Lung / drug therapy*
• Carcinoma, Non-Small-Cell Lung / genetics
• ErbB Receptors / genetics*
• Humans
• Lung Neoplasms / drug therapy*
• Lung Neoplasms / genetics
• Mutation*
• Protein Kinase Inhibitors / therapeutic use*
• Protein-Tyrosine Kinases / antagonists & inhibitors*
• Proto-Oncogene Proteins / genetics*
• Proto-Oncogene Proteins p21(ras)
• ras Proteins / genetics*